Archives
-
Beyond Reperfusion: Mapping Stroke Inflammation
2026-10-03
The post-stroke inflammatory response is increasingly understood as a determinant of recovery, not merely a consequence of tissue injury. Building on research linking esculetin, CKLF1, CCR5, and neutrophil trafficking, this thought-leadership article examines how translational teams can distinguish target association from mechanistic dependency. It also positions ICI 118,551 hydrochloride as a focused pharmacological probe for exploring whether adrenergic signaling intersects with inflammatory recruitment, while emphasizing evidence boundaries, model limitations, and the need for human-relevant validation.
-
Sodium phosphate dibasic: Buffer Workflows
2026-10-01
Build reproducible biological assay buffers with Sodium phosphate dibasic while controlling concentration, temperature, pH, and storage. This practical guide also shows how phosphate-buffer screening can support nucleic acid–lipid nanoparticle workflows without overstating compatibility or stability.
-
circEIF2S2 Drives CRC Progression Through miR-646/UHMK1
2026-10-01
This 2026 study identifies an EIF4A3–circEIF2S2–miR-646–UHMK1 pathway that connects circular RNA biogenesis with colorectal cancer proliferation, metastasis, and immune suppression. Its combined molecular, cellular, co-culture, and xenograft evidence positions circEIF2S2 as a mechanistic and potentially actionable regulator rather than only a disease-associated biomarker.
-
CA-074: Selective Cathepsin B Inhibitor
2026-10-01
CA-074 is a selective cathepsin B inhibitor with a reported Ki of 2–5 nM and weaker reported activity against cathepsins H and L. It provides a research tool for testing cathepsin B in lysosomal membrane permeabilization, cancer metastasis, neurotoxicity, and immune response modulation.
-
GOB-38 in E. anophelis: Enzyme and Resistance
2026-09-30
The reference study characterizes GOB-38, a B3 metallo-β-lactamase from Elizabethkingia anophelis, by combining recombinant expression, biochemical profiling, genome analysis, and bacterial co-culture. Its broad substrate range and distinctive active-site residues connect enzyme-level properties with clinically important carbapenem resistance and possible resistance exchange during co-infection.
-
MDL 28170: Calpain Inhibitor Lab Guide
2026-09-29
A scenario-based guide to using MDL 28170, Calpain and Cathepsin B Inhibitor, Selective (SKU A4412) in viability, apoptosis, neuroprotection, and protease-mechanism studies. It combines product specifications, peer-reviewed evidence, formulation guidance, controls, and vendor-selection considerations for more interpretable laboratory results.
-
Perphenazine Beyond Dopamine: A Translational Playbook
2026-09-29
Perphenazine is best understood not only as a dopamine D2 receptor antagonist, but also as a mechanistically rich research tool spanning neuropharmacology, mitochondrial biology, opioid tolerance suppression, and host-directed antibacterial research. This article translates the evidence into a practical framework for designing more rigorous, cross-domain experiments.
-
EZ Cap™ Cy5 Firefly Luciferase mRNA: Assay Logic
2026-09-28
EZ Cap Cy5 Firefly Luciferase mRNA enables a decision-oriented framework for separating delivery, intracellular localization, and translation. This article connects dual-reporter assay design with recent circular mRNA CAR-T findings to improve interpretation of advanced mRNA experiments.
-
6-FAM SE for Durable Biomolecule Labeling
2026-09-28
Use 6-FAM SE to add a stable fluorescein label to accessible primary amines on proteins, peptides, or amine-modified oligonucleotides—not to label unmodified DNA indiscriminately. Its amine-reactive chemistry also offers a practical way to build tracking assays inspired by stimulus-responsive nanomedicine, provided labeling is kept separate from claims about therapeutic function.
-
DAT Imaging Tracks Dopaminergic Graft Maturation
2026-09-27
Goggi et al. evaluated dopamine transporter PET as a non-invasive way to follow human stem cell-derived dopaminergic grafts in a rat model of Parkinson’s disease. Their results support [18F]FBCTT imaging as a marker of graft differentiation, while complementary imaging, behavioral testing, and histology provide distinct evidence about graft function and maturation.
-
Cathepsin B inhibitor CA-074: Practical Guide
2026-09-26
CA-074 is a small-molecule cathepsin B inhibitor for testing whether cathepsin B activity contributes to a biochemical or cellular phenotype. Use it with assay-specific controls and verify exposure in each model; the dossier does not establish a universal cell dose, cell-entry profile, or disease outcome.
-
Pexidartinib (PLX3397) in Microglia Research
2026-09-25
Use Pexidartinib (PLX3397) to test whether CSF1R-dependent microglial biology contributes to alcohol-associated changes in hippocampal circuits—without treating a tumor-focused inhibitor as an established seizure intervention. This guide translates a recent microglia study into a cautious, target-engagement-led workflow with practical dosing, controls, and troubleshooting.
-
DEBIO 1143 Redirects Cell Death in Murine TNBC
2026-09-25
An integrated study of murine triple-negative breast cancer models links DEBIO 1143 exposure to cIAP1 depletion and shifts toward necroptosis-like and autophagy-associated responses, rather than increased apoptosis. Combining viability and cell-death assays with molecular dynamics, the work offers a mechanistic framework while leaving important questions about causality and clinical transfer unresolved.
-
MDL 28170 for Calpain-Linked Neuroprotection
2026-09-24
MDL 28170 offers a practical way to test whether excessive calpain activity contributes to neuronal and synaptic injury, including the BDNF/TrkB disruption reported after maternal surgery in pregnant rats. This guide translates that finding into controlled cell and tissue workflows, with pilot conditions, assay-selection advice, and limits on interpreting a dual calpain/cathepsin B inhibitor.
-
Vasopressin Analogues: Receptor Biology and Design
2026-09-24
Glavaš and colleagues review how structural changes to vasopressin alter receptor activity, stability, and therapeutic use, linking peptide structure to applications such as desmopressin for antidiuresis and terlipressin for vasoconstriction. Their synthesis is useful for choosing research models, while also emphasizing that emerging antiviral proposals remain preliminary and should not be treated as established clinical effects.